((自动化翻译由路透提供，请见免责声明 )) (在第2段和第3段增加了试验细节，并增加了股份)
路透10月8日 - Sage Therapeutics 周二表示，由于在一项中期试验中没有达到主要目标，该公司 将停止 开发治疗阿尔茨海默病的试验性药物 ，这导致其股价在盘前交易中下跌约20%，至5.30美元。
在对 174 名患者进行的试验中，dalzanemdor 作为阿尔茨海默氏症患者轻度认知障碍和轻度痴呆的治疗药物，与安慰剂相比没有显示出统计学上的显著差异。
该公司表示，它将继续把 dalzanemdor 作为亨廷顿氏病的治疗药物进行测试，预计将在今年晚些时候报告中期试验数据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.